Home > Journals > International Angiology > Past Issues > International Angiology 2017 June;36(3) > International Angiology 2017 June;36(3):254-60



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



International Angiology 2017 June;36(3):254-60

DOI: 10.23736/S0392-9590.16.03734-2


language: English

Patterns and determinants of use of pharmacological therapies for intermittent claudication in PAD outpatients: results of the IDOMENEO study

Claudio CIMMINIELLO 1, Hernan POLO FRIZ 1, 2, Giuseppe MARANO 3, Guido ARPAIA 4, Patrizia BORACCHI 3, Gabriella SPEZZIGU 2, Adriana VISONÀ 5 , on behalf of SIAPAV Investigators 

1 Center for Studies and Research, Italian Society of Angiology and Vascular Pathology (Società Italiana di Angiologia e Patologia Vascolare, SIAPAV), Milan, Italy; 2 Unit of Internal Medicine, Medical Department, Vimercate Hospital, Vimercate, Monza-Brianza, Italy; 3 G. A. Maccacaro Laboratory of Medical Statistics, Epidemiology and Biometry, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 4 Unit of Internal Medicine, Medical Department, Carate Hospital, Carate Brianza, Monza-Brianza, Italy; 5 Department of Vascular Medicine, Castelfranco Veneto Hospital, Castelfranco Veneto, Treviso, Italy


BACKGROUND: Peripheral arterial disease (PAD) usually presents with intermittent claudication (IC). The aim of the present study was to assess, in clinical practice, the pattern of use of pharmacological therapies for IC in stable PAD outpatients.
METHODS: A propensity analysis was performed using data from the IDOMENEO study, an observational prospective multicenter cohort study. The association between any pharmacological symptomatic IC therapy with different variables was investigated using generalized linear mixed models with pharmacological therapy as response variable and binomial error.
RESULTS: Study population: 213 patients, male sex 147 (69.0%), mean age 70.0±8.6 years. Only 36.6% was under pharmacological treatment for IC, being cilostazol the most used medication (21.6%). Univariate analysis showed a probability of a patient of being assigned to any pharmacological symptomatic IC therapy of 67.0% when Ankle-Brachial Index (ABI) <0.6 and 29.8% when ABI>0.6 (P=0.0048), and a propensity to avoid pharmacological treatment for patients with a high number of drugs to treat cardiovascular risk factors (probability of 55.2% for <4 drugs and 19.6% for >4 drugs, P=0.0317). Multivariate analysis confirmed a higher probability of assigning treatment for ABI<0.6 (P=0.0274), and a trend to a lower probability in patients under polypharmacy (>4 drugs: OR=0.13, P=0.0546).
CONCLUSIONS: In clinical practice, only one third of stable outpatients with IC used symptomatic pharmacological therapy for IC. We found a propensity of clinicians to assign any symptomatic pharmacological IC therapy to patients with lower values of ABI and a propensity to avoid this kind of treatment in patients under polypharmacy.

KEY WORDS: Peripheral arterial disease - Intermittent claudication - Therapeutics - Patient compliance

top of page